9 Green Days In A Row: BridgeBio Pharma Stock Is Up 14%
A biotech stock’s long winning streak puts its high growth and deep losses into sharp focus.
BridgeBio Pharma (BBIO), Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. Its stock has now moved higher for 9 consecutive trading days, a run that has produced a cumulative gain of 13.5% and added about $1.8 Bil to the company’s market value.
The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
The Streak Next To The S&P 500
Here is how BBIO stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | BBIO | S&P 500 |
|---|---|---|
| 1D | 0.2% | -0.4% |
| 9D (Current Streak) | 13.5% | 1.9% |
| 1M (21D) | 15.7% | -1.1% |
| 3M (63D) | 7.8% | 13.5% |
| YTD 2026 | 1.9% | 9.6% |
| 2025 | 178.8% | 16.4% |
| 2024 | -32.0% | 23.3% |
| 2023 | 429.8% | 24.2% |
What does the data show behind the run?
The move appears specific to the stock. Over the same 9 trading days the S&P 500 returned +1.9%. The fundamental picture is complex, showing extreme growth against deep losses. BridgeBio’s revenue over the last twelve months grew 355.2%, far outpacing the S&P 500 median of 7.5%.
Yet its operating margin is -86.9% and it trades at a price-to-earnings multiple of -21.0, against S&P 500 medians of 18.5% and 24.9, respectively. For market context, 67 S&P 500 stocks are currently on winning streaks of 3 days or more.
A streak is information, not an instruction.
A persistent move like this is a clear signal of momentum and investor attention. It is not, however, a direct command to buy or sell. The disciplined approach is to use the new information as a prompt. It is a reason to check the business fundamentals against the new price, which now stands at about $15 Bil in total market value. The contrast between the company’s growth and its current profitability is the core tension to evaluate.
If you are hunting for strength that has more behind it than a hot take, our Guidance Momentum screen surfaces the names where management raised its own outlook, which is the kind of momentum that tends to persist.
And for anyone who would rather own the whole group than one company’s story, a biotech ETF like XBI owns the whole group. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy
A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?
The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Follow the story; invest in the strategy.